Trxade Group EBIT per Share
EBIT per Share of Trxade Group (MEDS) as of Aug 10, 2026.
Get this data via API
Financial Data API
EBIT per Share
0.00USD
Last updated:
EBIT per Share of Trxade Group is 2026 0.00 USD. EBIT per Share of Trxade Group was 2025 0.00 USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Trxade Group Stock analysis
What does Trxade Group do? The Trxade Group Inc is a US-American company that was founded in 2010 and has its headquarters in Tampa, Florida. The company is engaged in the development and operation of an online platform for trading pharmaceuticals and medical products for healthcare facilities and pharmacies.
The business model of Trxade is to facilitate and streamline the purchase of pharmaceuticals and medical products for smaller healthcare facilities and pharmacies. To do this, the company operates an online platform that allows customers to order their needed products directly from various suppliers. By using the platform, customers can save time and costs as they no longer have to inquire with various suppliers and place individual orders for products. Instead, they can handle all their orders through the platform and thereby have access to a wider range of products and better prices.
Trxade offers its customers various divisions. The main division is the trade of generic pharmaceuticals. Here, the company works closely with various suppliers and manufacturers to offer its customers a wide range of medications. Generic pharmaceuticals are usually cheaper than brand-name medications, allowing the company's customers to save costs. In addition, Trxade also offers other medical products such as vaccines, diagnostics, and medical accessories.
Another business area of Trxade is the operation of pharmacies. The company operates several pharmacies under the brand name "Bonum Health," which offer a wide range of medical services. These include, for example, telehealth services, where patients can receive medical advice and assistance from licensed doctors via video call. The pharmacies also offer a wide range of prescription and over-the-counter medications.
Trxade has undergone remarkable development in recent years. In 2016, the company went public and in 2019 had a revenue of around 10 million US dollars. Trxade now has over 11,000 registered customers and collaborates with over 450 suppliers and manufacturers.
Overall, Trxade is an innovative company focused on simplifying and improving the trade of pharmaceuticals and medical products for smaller healthcare facilities and pharmacies. With its wide range of generic pharmaceuticals, medical accessories, and telehealth services, the company has established a strong position in the market and is expected to continue growing in the coming years. Trxade Group is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Trxade Group stock
On Eulerpool you can find the complete historical development of EBIT per Share Trxade Group since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Trxade Group
All Key Metrics — Trxade Group
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth